[go: up one dir, main page]

TR201100151A2 - İbandronate formülasyonu. - Google Patents

İbandronate formülasyonu.

Info

Publication number
TR201100151A2
TR201100151A2 TR2011/00151A TR201100151A TR201100151A2 TR 201100151 A2 TR201100151 A2 TR 201100151A2 TR 2011/00151 A TR2011/00151 A TR 2011/00151A TR 201100151 A TR201100151 A TR 201100151A TR 201100151 A2 TR201100151 A2 TR 201100151A2
Authority
TR
Turkey
Prior art keywords
ibandronate
formulation
ibandronate formulation
prevention
pharmaceutically acceptable
Prior art date
Application number
TR2011/00151A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/00151A priority Critical patent/TR201100151A2/tr
Priority to TR2011/10526A priority patent/TR201110526A2/tr
Priority to TR2011/10524A priority patent/TR201110524A2/tr
Priority to TR2011/10525A priority patent/TR201110525A2/tr
Priority to PCT/TR2012/000008 priority patent/WO2012093977A1/en
Priority to PCT/TR2012/000010 priority patent/WO2012093979A1/en
Priority to EP12704937.7A priority patent/EP2661270A1/en
Priority to PCT/TR2012/000006 priority patent/WO2012093975A1/en
Priority to PCT/TR2012/000007 priority patent/WO2012093976A1/en
Publication of TR201100151A2 publication Critical patent/TR201100151A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş; kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere geliştirilmiş ibandronat ve/veya farmasötik açıdan uygun herhangi bir türevini içeren suda çözünür dozaj formlarını açıklamaktadır.
TR2011/00151A 2011-01-06 2011-01-06 İbandronate formülasyonu. TR201100151A2 (tr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.
TR2011/10526A TR201110526A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik formülasyonlar.
TR2011/10524A TR201110524A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.
TR2011/10525A TR201110525A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.
PCT/TR2012/000008 WO2012093977A1 (en) 2011-01-06 2012-01-03 Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
PCT/TR2012/000010 WO2012093979A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
EP12704937.7A EP2661270A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
PCT/TR2012/000006 WO2012093975A1 (en) 2011-01-06 2012-01-06 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.

Publications (1)

Publication Number Publication Date
TR201100151A2 true TR201100151A2 (tr) 2012-07-23

Family

ID=46457629

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.

Country Status (3)

Country Link
EP (1) EP2661270A1 (tr)
TR (1) TR201100151A2 (tr)
WO (1) WO2012093979A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104922060B (zh) * 2015-05-23 2017-10-20 河北仁合益康药业有限公司 一种伊班膦酸钠注射液组合物
CN107670103A (zh) * 2017-09-15 2018-02-09 天津大学 聚乙烯吡络烷酮改性的骨水泥及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
AU712710B2 (en) * 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
EP2661270A1 (en) 2013-11-13
WO2012093979A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
PH12017501306A1 (en) Inhibitors of histone demethylases
IN2014DN10670A (tr)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
IN2014MN00948A (tr)
TW201129382A (en) Antibody formulation and therapeutic regimens
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201691695A1 (ru) Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
PH12014500386A1 (en) Combination treatment for hepatitis c
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
EA201270728A1 (ru) Пуриновые соединения
TR201004464A2 (tr) Kemik erimesi için formülasyon.
EA201171414A1 (ru) Ингибиторы белков семейства iap
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX2014012321A (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
TR201100151A2 (tr) İbandronate formülasyonu.